Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...
Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...
The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback